What did @dr.thibaut.coste actually say?
The transcript provided is garbled and uninterpretable, likely the result of a failed auto-transcription of French-language audio. The video caption, however, makes the central claim clear: a new study suggests that Wegovy (semaglutide) and Mounjaro (tirzepatide) might be taken every two weeks instead of every week, and the results are described as "very interesting." The linked study in the caption points to a real, peer-reviewed publication in Obesity (Wiley), so the claim has a traceable source.
Because the spoken transcript is not usable, this fact-check evaluates the claim as stated in the caption and as supported by the linked study. The core question is whether biweekly dosing of GLP-1 receptor agonists produces meaningful weight loss outcomes, and whether that framing is responsible to promote to a general audience.
Does the science back this up?
Partially, but the framing needs significant caveats. The linked study (DOI: 10.1002/oby.70137) appears to examine extended dosing intervals for GLP-1 receptor agonists, which is a legitimate area of emerging research. However, "very interesting results" is doing a lot of work here.
Current prescribing guidelines from the FDA and EMA specify weekly subcutaneous injection for both semaglutide (Wegovy) and tirzepatide (Mounjaro). These dosing schedules were established through large-scale phase 3 trials, including the STEP trials for semaglutide (Wilding et al., 2021, NEJM) and the SURMOUNT trials for tirzepatide (Jastreboff et al., 2022, NEJM), which enrolled thousands of participants over 68-72 weeks using weekly dosing.
A single preliminary study exploring biweekly dosing does not overturn those approvals. Pharmacokinetic data for semaglutide shows a half-life of approximately one week, which is precisely why weekly dosing was selected. Stretching to two weeks risks inadequate drug exposure for a meaningful portion of the dosing interval, potentially reducing efficacy or causing fluctuating side effects.
What did they get wrong (or right)?
Credit where it is due: citing an actual peer-reviewed study with a direct link is more responsible than most TikTok health content. The caption does not claim biweekly dosing is equivalent to weekly dosing or instruct viewers to change their own regimens without consulting a doctor, at least not explicitly.
The problem is the framing. Describing a single early study's results as "very interesting" to a combined French-speaking audience watching a video tagged with weight-loss hashtags creates an expectation that this is clinically actionable. It is not. Most viewers will not read the study. They will hear a doctor say you might be able to inject every two weeks and conclude that halving their injection frequency is a reasonable, validated option.
That is a real risk. Patients who self-modify their GLP-1 dosing intervals without medical supervision may experience reduced efficacy, weight regain, or altered tolerability. The video caption does not include a disclaimer advising against self-modification of dosing schedules, which is a meaningful omission for a regulated medication.
What should you actually know?
Biweekly dosing of GLP-1 receptor agonists is genuinely being studied, and the research is worth watching. There are legitimate clinical scenarios, including cost constraints and injection fatigue, that make extended dosing intervals worth investigating. But "being studied" and "clinically validated" are not the same thing.
Both Wegovy and Mounjaro are approved for weekly subcutaneous injection. Changing your dosing interval is a clinical decision that requires a prescriber's involvement. Some patients have informally stretched doses due to shortages or cost, and some have reported maintaining results, but anecdote is not evidence, and the STEP and SURMOUNT trials were not designed to evaluate biweekly dosing.
If you are on one of these medications and are considering changing your schedule because of cost, tolerability, or supply issues, talk to your prescribing clinician. There may be a medically supervised tapering or extended-interval protocol appropriate for your situation. Do not make that change based on a TikTok caption summarizing a single preliminary study.